Michael Gelband’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Michael Gelband’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-284,457	Closed	-$23.1M	–	2029
2025 Q1	$23.1M	Buy	284,457 +217,540	+325%	+$19.4M	0.23%	85
2024 Q4	$6.03M	Buy	+66,917	New	+$6.48M	0.04%	399
2021 Q4	–	Sell	-50,593	Closed	-$6.36M	–	2657
2021 Q3	$6.36M	Buy	50,593 +42,793	+549%	+$5.51M	0.09%	317
2021 Q2	$1.06M	Buy	+7,800	New	+$1.03M	0.01%	988
2020 Q4	–	Sell	-1,800	Closed	-$201K	–	2433
2020 Q3	$201K	Buy	+1,800	New	+$202K	﹤0.01%	1473
2020 Q1	–	Sell	-73,083	Closed	-$6.95M	–	1699
2019 Q4	$6.95M	Buy	+73,083	New	+$6.32M	0.13%	129

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Michael Gelband's XBI Position: Q2 2025 in Review

Michael Gelband sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2025, closing a stake of 284,457 shares — an estimated $23.1M sold.

Michael Gelband first reported a position in XBI in Q4 2019 and held it in 6 quarters. The position peaked at $23.1M in Q1 2025. 625 funds tracked by Wall St. Rank hold XBI as of Q2 2025.

Michael Gelband reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2025 after selling out during the quarter.
Michael Gelband sold 284,457 State Street SPDR S&P Biotech ETF shares in Q2 2025, an estimated $23.1M.
Michael Gelband first reported a position in State Street SPDR S&P Biotech ETF in Q4 2019 and held it in 6 quarters.
Michael Gelband's State Street SPDR S&P Biotech ETF position peaked at $23.1M in Q1 2025.
625 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2025.

Based on ExodusPoint Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.